Case Report: Triple-Negative Breast Cancer Stage III, Female, age 41

  • Post comments:0 Comments
📄 5 mins.

Case study on complete remission using just fenbendazole – no chemotherapy or radiation. The patient in this case study is a 41-year-old woman, who had metastatic Stage III triple-negative breast cancer that had spread to her lymph nodes. According to the Cleveland Clinic, 15% of cases of invasive breast cancer are triple-negative breast cancer (TBNC), which is considered a dangerous subtype of the disease.

Triumph Over Adversity: Beating Triple Negative Breast Cancer with Fenbendazole

The woman was diagnosed with Stage III triple negative breast cancer in October 2022 after she noticed some changes on the skin of her breast, along with pain. They diagnosed her with triple-negative breast cancer, which was confirmed by a CT scan, biopsy, and mammography.

She had stage 3 triple-negative breast cancer involving lymph nodes.

Unfortunately, the cancer had spread to the lymph nodes, which is what caused the skin on her breast to change color.

  • She decided to take Fenbendazole for 14 weeks and started the 3 days on, 4 days off protocol that I read about for about the first 7 weeks.
  • Then that regime increased from 3 capsules a week to 5 capsules of 222 mg a week.

11 Weeks After Taking Fenbendazole

The first change she observed was her skin beginning to clear up. Incredibly, 11 weeks after starting Fenbendazole the spots on her breast had completely disappeared. This was the 222-mg dose. There were no side effects at all.

She advises anyone in the same situation to keep taking Fenben and don’t stop till it’s gone. She has been free from cancer for almost 16 months. Don’t give up and best wishes to everyone!

Questions and Answers

Q: Are there any side effects from Fenbendazole?
A: No.

Q: Did you do any other treatments?
A: No.

Q: Did you tell your doctor you were using Fenbendazole?
A: No.

Q: What is your weight?
A: 5’6″ and 145 pounds.

Q: Did you receive any booster shots or COVID-19 shots?
A: None.

A Woman Eradicates Metastatic Breast Cancer in Just 4 Months

The case of the woman in this report supports the idea that Fenbendazole can effectively treat cancer that has metastasized in individuals. To say it treated her triple-negative breast cancer is an understatement, as it completely got rid of the cancer within 4 months. It’s important to note that she only used Fenbendazole and no other normal cancer treatments.

  • She carefully dosed herself with Fenbendazole.
  • For the first seven weeks, she took 222 mg of Fenbendazole for three days in a row each week.
  • Then, for seven more weeks, she increased to taking it five times a week.

The spots and discolored skin on her breast went away at 11 weeks (secondary breast cancer can form just under the skin, so you can see it as spots). This type of cancer happened in her skin after the original cancer spread from her breast.

Victory Over Cancer: Inspiring New Treatment Hopes

At about 16 weeks, the woman received validation of her suspicions: medical testing demonstrated that she was cancer-free. The skin lesions she had originally noticed disappearing were gone. It had now been approximately 52 weeks since her initial diagnosis, and fortunately, she was symptom-free and devoid of cancer.

These results are amazing. Along with what we saw before in lab tests of fenbendazole, it makes you think this drug might beat cancer. But not everything is always obvious. There could be unknown reasons why people react differently or other reasons that cause outstanding results like these.

Breakthrough in Cancer Research: Fenbendazole Shows Promising Results Against Metastasis

As a review, Joe N.S. and the other researchers (2022) decided to perform tests to see if Mebendazole could safely stop cancer from spreading to other parts of the animals.

  • They thought triple-negative breast cancer would be a good type of cancer to test.
  • They wanted to see if Fenbendazole could prevent the cancer from going to other areas after starting in the breast.

Using lab and animal tests Joe N.S. and the other researchers learned:

  • Fenbendazole prevented liver metastasis
  • Fenbendazole decreased distant lung metastasis
  • Fenbendazole eradicated triple-negative breast cancer that had previously been diagnosed.

After treatment with Fenbendazole, there was a big drop in the cell marker Integrin β4 (ITGβ4). This marker is usually connected to cancer spreading to other places and stem cells growing more in faraway areas. These results likely apply to people too, even though most of the data came from animals.

Triple-Negative Breast Cancer

Triple-negative breast cancer cells are different from other breast cancer cells. This is because they don’t have the progesterone or estrogen receptors that other breast cancers have.

Chemotherapy is not a very good treatment for triple-negative breast cancer. This is because chemotherapy mostly works by attaching to hormone receptors. However, triple-negative breast cancer is missing these receptors.

The receptors are molecules on the outside of cells that grab onto substances and decide which substances can attach to cells and affect what the cells do.

Therefore, there’s an urgent need to find treatments that can treat TBNC.


Earlier research (experiments in Petrie dishes and with animals) showed Fenbendazole would likely work for treating triple-negative breast cancer in people. It was encouraging to find Fenbendazole good at lowering or taking out cancer stem cells that appear to be involved in metastatic spread and chemotherapeutic resistance (Joe et al., 2022). Doctors think stem cells help cancer spread to other parts of the body and stop chemotherapy from working.

Also, triple-negative breast cancer tends to grow fast, spreading to the liver, brain, lungs, and bones. It was important to test it on animals before trying it on people.


Gilkes, D. M., Oza, H. H., Riggins, Godet, I., Milki, N., G. J., Joe, N.S., & Ain, N. U. I., (2022). By suppressing the expression of ITGβ4 and cancer stemness, Mebendazole helps to stop distant organ metastases. Research on Breast Cancer, 24, 98.

Leave a Reply